• Share:

• Subscribe:

Queensland’s biomedical innovation continues to make waves globally, with Sanofi announcing it has acquired Vicebio, a company formed to develop The University of Queensland’s (UQ) Molecular Clamp vaccine technology.

This milestone reflects the strength of Queensland’s innovation ecosystem and the value of long-term global partnerships. Sanofi’s decision to acquire Vicebio is global recognition of Queensland’s research excellence.

Queensland’s research community continues to work closely with Sanofi on a range of projects through the Translational Science Hub, a collaboration between Sanofi, the Queensland Government, UQ, and Griffith University. The Hub connects world-class researchers in Queensland with Sanofi scientists, creating a first-of-its-kind, global scientific community focused on mRNA technology and translational science.

Now that Vicebio is a part of Sanofi, we look forward to more research by Sanofi in Queensland.

What is a Molecular Clamp?

It’s a technology developed by Queensland scientists that helps keep a key protein found on the outside of a virus in the right shape in a vaccine. This is important because the correct shape allows your immune system to recognise the protein and build a strong defence against disease.

This technology has the potential to be a game-changer for global health. It can be used for a wide range of viruses to trigger a powerful protective immune response.

From local discovery to global impact

Sanofi’s acquisition of Vicebio brings this Queensland-grown innovation into their global research and development pipeline, opening doors for further investment and collaboration.

The Queensland Government’s efforts to attract and support global biotech leaders like Sanofi are paying dividends. This deal validates the quality of Queensland’s biomedical research expertise and signals the depth of innovation that can contribute to global health solutions.

Executive Director – Sovereign Industries, Denise Johnston said this is a proud moment for Queensland’s biomedical research sector.

‘It shows how our partnerships with global leaders like Sanofi are delivering real outcomes for our state and the world,’ Ms Johnston said.

Jean-François Toussaint, Global Head of Research and Development Vaccines at Sanofi said, The University of Queensland’s Molecular Clamp technology has the potential to accelerate vaccine development and aligns strongly with Sanofi’s mission to deliver innovative solutions to global health challenges.

‘We’re excited to help realise the potential of this breakthrough technology and advance the development of next-generation vaccines that could protect millions worldwide,’ said Mr Toussaint.

Professor Deborah Terry, UQ Vice-Chancellor AC, said the acquisition was an incredible milestone for biomedical research and innovation, not just at UQ but across Australia.

‘The extraordinary effort over 12 years by UQ researchers, in pursuit of research with the potential to improve health outcomes for people around the world has been truly inspiring. I offer them a heartfelt congratulations,’ Professor Terry said.

This is more than a commercial deal – it’s evidence of Queensland’s biomedical innovation reaching the world stage.

• Share:

• Subscribe: